

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/583,342	05/31/2000	Frederic Bushman	1211.002US1	2389
21186	7590 03/26/2002			
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.			EXAMINER	
P.O. BOX 293 MINNEAPOI	38 LIS, MN 55402		SOUAYA, JEHANNE E	
			ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 03/26/2002	J

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

09/583,342

Bushman et al

Examiner

Jehanne Souaya

Art Unit 1634



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence add				
	for Reply	TO EVENE				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH(S) FROM				
	nsions of time may be available under the provisions of 37 C ter SIX (6) MONTHS from the mailing date of this communic		timely filed			
- If the	period for reply specified above is less than thirty (30) days considered timely.		days will			
- If NO	period for reply is specified above, the maximum statutory immunication.	period will apply and will expire SIX (6) MONTHS from	n the mailing date of this			
- Failui - Any	re to reply within the set or extended period for reply will, by reply received by the Office later than three months after the rned patent term adjustment. See 37 CFR 1.704(b).					
Status						
1) X	Responsive to communication(s) filed on Nov 2, 20	001	•			
2a) 🗌	This action is FINAL . 2b) 💢 This act	tion is non-final.				
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposi	tion of Claims					
4) X	Claim(s) 1-16, 20, and 21	is/are pending in the	ne application.			
4	la) Of the above, claim(s)	is/are withdrawn	from consideration.			
5) 🗔	Claim(s)	is/are allowed	.k			
6) 🗆	Claim(s)	is/are rejecte	d.			
7) 🗆	Claim(s)	is/are objecte	ed to.			
8) 🗶	Claims 1-16, 20, and 21	are subject to restriction and/or e	lection requirement.			
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	objected to by the Examiner.				
11)	The proposed drawing correction filed on	is: a)□ approved b)□ disappro	oved.			
12)	The oath or declaration is objected to by the Exam	iner.				
Priority	under 35 U.S.C. § 119					
_	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).				
a) L	All b)☐ Some* c)☐ None of:					
	1. Certified copies of the priority documents have					
	2. Certified copies of the priority documents have		•			
	 Copies of the certified copies of the priority d application from the International Bure se the attached detailed Office action for a list of th 	eau (PCT Rule 17.2(a)).	Stage			
14)	Acknowledgement is made of a claim for domestic					
Attachm	ent(s)					
_	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).				
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)				
17) 🔲 Im	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:				

Application/Control Number: 09/583,342 Page 2

Art Unit: 1634

DETAILED ACTION

The following restriction requirement is being set forth as a group was inadvertently left out of the previous restriction requirement.

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-16 and 20, drawn to a method and kit for detecting compounds that modulate topoisomerase activity, classified in class 435, subclass 6.
 - II. Claim 21, drawn to a method of screening compounds capable of modulating nucleic acid modifying enzymatic activity, classified in class 435, subclass 6.
- 2. The inventions are distinct, each from the other because of the following reasons: The methods of group I encompass the sep of assaying for nucleic acid religation, whereas the methods of group II encompass methods of assaying for nucleic acid cleavage, which require different reagents, reaction parameters and reaction conditions. The method of screening compounds capable of modulating nucleic acid-modifying enzymatic activity of group II encompasses detecting compounds that modulate enzymes other than topoisomerases, and the step of assaying for nucleic acid *cleavage* does not appear to be obvious over the method of detecting compounds that modulate topoisomerase activity by assaying for nucleic acid *religation*, nor does the method step of assaying for nucleic acid cleavage appear to be needed, or encompassed by the method steps of the method of group I. Further, the step of assaying for

Application/Control Number: 09/583,342 Page 3

Art Unit: 1634

nucleic acid religation of group II encompasses a step that could be used in a method of detecting modulators of nucleic acid ligases.

- 3. Because these inventions are distinct for the reasons given above and the search required for Group II is not required for Group I, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703)308-6565. The examiner can normally be reached Monday-Friday from 9:00 AM to 6:00 PM.

Application/Control Number: 09/583,342

Page 4

Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya
Patent examiner

Art Unit 1634

March 22, 2002